Literature DB >> 30575890

Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody.

Divyanshu Dubey1,2, Sean J Pittock1,2, Karl N Krecke3, Padraig P Morris3, Elia Sechi1, Nicholas L Zalewski1, Brian G Weinshenker1, Eslam Shosha1, Claudia F Lucchinetti1, James P Fryer1, A Sebastian Lopez-Chiriboga1,2, John C Chen1,4, Jiraporn Jitprapaikulsan2, Andrew McKeon1,2, Avi Gadoth1, B Mark Keegan1, Jan-Mendelt Tillema1, Elie Naddaf1, Marc C Patterson1, Kevin Messacar5, Kenneth L Tyler6, Eoin P Flanagan1,2.   

Abstract

Importance: Recognizing the characteristics of myelin oligodendrocyte glycoprotein autoantibody (MOG-IgG) myelitis is essential for early accurate diagnosis and treatment. Objective: To evaluate the clinical, radiologic, and prognostic features of MOG-IgG myelitis and compare with myelitis with aquaporin-4-IgG (AQP4-IgG) and multiple sclerosis (MS). Design, Setting, and Participants: We retrospectively identified 199 MOG-IgG-positive Mayo Clinic patients from January 1, 2000, through December 31, 2017, through our neuroimmunology laboratory. Fifty-four patients met inclusion criteria of (1) clinical myelitis; (2) MOG-IgG positivity; and (3) medical records available. We excluded 145 patients without documented myelitis. Myelitis of AQP4-IgG (n = 46) and MS (n = 26) were used for comparison. Main Outcomes and Measures: Outcome variables included modified Rankin score and need for gait aid. A neuroradiologist analyzed spine magnetic resonance imaging of patients with MOG-IgG and control patients blinded to diagnosis.
Results: Of 54 included patients with MOG-IgG myelitis, the median age was 25 years (range, 3-73 years) and 24 were women (44%). Isolated transverse myelitis was the initial manifestation in 29 patients (54%), and 10 (19%) were initially diagnosed as having viral/postviral acute flaccid myelitis. Cerebrospinal fluid-elevated oligoclonal bands occurred in 1 of 38 (3%). At final follow-up (median, 24 months; range, 2-120 months), 32 patients (59%) had developed 1 or more relapses of optic neuritis (n = 31); transverse myelitis (n = 7); or acute disseminated encephalomyelitis (n = 1). Clinical features favoring MOG-IgG myelitis vs AQP4-IgG or MS myelitis included prodromal symptoms and concurrent acute disseminated encephalomyelitis. Magnetic resonance imaging features favoring MOG-IgG over AQP4-IgG or MS myelitis were T2-signal abnormality confined to gray matter (sagittal line and axial H sign) and lack of enhancement. Longitudinally extensive T2 lesions were of similar frequency in MOG-IgG and AQP4-IgG myelitis (37 of 47 [79%] vs 28 of 34 [82%]; P = .52) but not found in MS. Multiple spinal cord lesions and conus involvement were more frequent with MOG-IgG than AQP4-IgG but not different from MS. Wheelchair dependence at myelitis nadir occurred in one-third of patients with MOG-IgG and AQP4-IgG but never with MS, although patients with MOG-IgG myelitis recovered better than those with AQP4-IgG. Conclusions and Relevance: Myelitis is an early manifestation of MOG-IgG-related disease and may have a clinical phenotype of acute flaccid myelitis. We identified a variety of clinical and magnetic resonance imaging features that may help clinicians identify those at risk in whom MOG-IgG should be tested.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30575890      PMCID: PMC6440233          DOI: 10.1001/jamaneurol.2018.4053

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  36 in total

1.  Outcomes of Colorado children with acute flaccid myelitis at 1 year.

Authors:  Jan A Martin; Kevin Messacar; Michele L Yang; John A Maloney; Jennifer Lindwall; Terri Carry; Patricia Kenyon; Stefan H Sillau; Joyce Oleszek; Kenneth L Tyler; Samuel R Dominguez; Teri L Schreiner
Journal:  Neurology       Date:  2017-06-14       Impact factor: 9.910

2.  Treatment of acute transverse myelitis and its early complications.

Authors:  Benjamin M Greenberg
Journal:  Continuum (Minneap Minn)       Date:  2011-08

3.  Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis.

Authors:  Maciej Jurynczyk; Ruth Geraldes; Fay Probert; Mark R Woodhall; Patrick Waters; George Tackley; Gabriele DeLuca; Saleel Chandratre; Maria I Leite; Angela Vincent; Jacqueline Palace
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

4.  Clinical presentation and prognosis in MOG-antibody disease: a UK study.

Authors:  Maciej Jurynczyk; Silvia Messina; Mark R Woodhall; Naheed Raza; Rosie Everett; Adriana Roca-Fernandez; George Tackley; Shahd Hamid; Angela Sheard; Gavin Reynolds; Saleel Chandratre; Cheryl Hemingway; Anu Jacob; Angela Vincent; M Isabel Leite; Patrick Waters; Jacqueline Palace
Journal:  Brain       Date:  2017-12-01       Impact factor: 13.501

5.  Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders.

Authors:  Eoin P Flanagan; Brian G Weinshenker; Karl N Krecke; Vanda A Lennon; Claudia F Lucchinetti; Andrew McKeon; Dean M Wingerchuk; Elizabeth A Shuster; Yujuan Jiao; Erika S Horta; Sean J Pittock
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

6.  Ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorders.

Authors:  Nicholas L Zalewski; Padraig P Morris; Brian G Weinshenker; Claudia F Lucchinetti; Yong Guo; Sean J Pittock; Karl N Krecke; Timothy J Kaufmann; Dean M Wingerchuk; Neeraj Kumar; Eoin P Flanagan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-12-02       Impact factor: 10.154

Review 7.  Acute flaccid myelitis: A clinical review of US cases 2012-2015.

Authors:  Kevin Messacar; Teri L Schreiner; Keith Van Haren; Michele Yang; Carol A Glaser; Kenneth L Tyler; Samuel R Dominguez
Journal:  Ann Neurol       Date:  2016-08-04       Impact factor: 10.422

8.  Discriminating long myelitis of neuromyelitis optica from sarcoidosis.

Authors:  Eoin P Flanagan; Timothy J Kaufmann; Karl N Krecke; Allen J Aksamit; Sean J Pittock; B Mark Keegan; Caterina Giannini; Brian G Weinshenker
Journal:  Ann Neurol       Date:  2016-02-12       Impact factor: 10.422

9.  Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis.

Authors:  Shin H Kang; Ying Li; Masahiro Fukaya; Ileana Lorenzini; Don W Cleveland; Lyle W Ostrow; Jeffrey D Rothstein; Dwight E Bergles
Journal:  Nat Neurosci       Date:  2013-03-31       Impact factor: 24.884

Review 10.  A clinical approach to diagnosis of autoimmune encephalitis.

Authors:  Francesc Graus; Maarten J Titulaer; Ramani Balu; Susanne Benseler; Christian G Bien; Tania Cellucci; Irene Cortese; Russell C Dale; Jeffrey M Gelfand; Michael Geschwind; Carol A Glaser; Jerome Honnorat; Romana Höftberger; Takahiro Iizuka; Sarosh R Irani; Eric Lancaster; Frank Leypoldt; Harald Prüss; Alexander Rae-Grant; Markus Reindl; Myrna R Rosenfeld; Kevin Rostásy; Albert Saiz; Arun Venkatesan; Angela Vincent; Klaus-Peter Wandinger; Patrick Waters; Josep Dalmau
Journal:  Lancet Neurol       Date:  2016-02-20       Impact factor: 44.182

View more
  56 in total

1.  Expanding the spectrum of MOG antibody disease.

Authors:  Michael Levy
Journal:  Mult Scler       Date:  2019-04-01       Impact factor: 6.312

Review 2.  Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.

Authors:  Deena A Tajfirouz; M Tariq Bhatti; John J Chen
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

3.  Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies.

Authors:  Elia Sechi; Karl N Krecke; Sean J Pittock; Divyanshu Dubey; A Sebastian Lopez-Chiriboga; Amy Kunchok; Brian G Weinshenker; Nicholas L Zalewski; Eoin P Flanagan
Journal:  Mult Scler       Date:  2020-02-27       Impact factor: 6.312

4.  MRI differences between MOG antibody disease and AQP4 NMOSD.

Authors:  Sara Salama; Majid Khan; Amirali Shanechi; Michael Levy; Izlem Izbudak
Journal:  Mult Scler       Date:  2020-01-15       Impact factor: 6.312

Review 5.  Myelin oligodendrocyte glycoprotein antibodies in neurological disease.

Authors:  Markus Reindl; Patrick Waters
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

6.  Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.

Authors:  Haojie Xie; Yingzhe Shao; Juan Du; Yajun Song; Yanfei Li; Ranran Duan; Yaobing Yao; Zhe Gong; Junfang Teng; Yanjie Jia
Journal:  J Neurol       Date:  2021-08-12       Impact factor: 4.849

Review 7.  Acute flaccid myelitis: cause, diagnosis, and management.

Authors:  Olwen C Murphy; Kevin Messacar; Leslie Benson; Riley Bove; Jessica L Carpenter; Thomas Crawford; Janet Dean; Roberta DeBiasi; Jay Desai; Matthew J Elrick; Raquel Farias-Moeller; Grace Y Gombolay; Benjamin Greenberg; Matthew Harmelink; Sue Hong; Sarah E Hopkins; Joyce Oleszek; Catherine Otten; Cristina L Sadowsky; Teri L Schreiner; Kiran T Thakur; Keith Van Haren; Carolina M Carballo; Pin Fee Chong; Amary Fall; Vykuntaraju K Gowda; Jelte Helfferich; Ryutaro Kira; Ming Lim; Eduardo L Lopez; Elizabeth M Wells; E Ann Yeh; Carlos A Pardo
Journal:  Lancet       Date:  2020-12-23       Impact factor: 79.321

Review 8.  Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment.

Authors:  Sidney M Gospe; John J Chen; M Tariq Bhatti
Journal:  Eye (Lond)       Date:  2020-12-15       Impact factor: 3.775

Review 9.  A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course.

Authors:  Jacqueline M Solomon; Friedemann Paul; Claudia Chien; Jiwon Oh; Dalia L Rotstein
Journal:  Ther Adv Neurol Disord       Date:  2021-05-09       Impact factor: 6.570

10.  Involvement of the Spinal Cord in Primary Mitochondrial Disorders: A Neuroimaging Mimicker of Inflammation and Ischemia in Children.

Authors:  C A P F Alves; A Goldstein; S R Teixeira; J S Martin-Saavedra; I P de Barcelos; G Fadda; L Caschera; M Kidd; F G Gonçalves; E M McCormick; M J Falk; Z Zolkipli-Cunningham; A Vossough; G Zuccoli
Journal:  AJNR Am J Neuroradiol       Date:  2020-12-31       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.